The report lists Apollo Hospitals Enterprise among the top losers, falling 1.33-2.66% range on the day.
Read this note →Apollo Hospitals Enterprise Limited
NSE APOLLOHOSP BSE 508869 INE437A01024
0 filings · 0 analysed
8,549.50
+5.91%
over 6 months
-
The report lists Apollo Hospitals Enterprise among the top losers, falling 1.33-2.66% range on the day.
-
HSIE Results Daily 06 Nov 26 HSIE
The report says Apollo's EBITDA grew 29% YoY across hospitals, HealthCo and AHLL segments, and raises concerns on trade margin impact on oncology while retaining BUY with revised TP INR9,990.
-
The report lists Apollo Hospitals Enterprise among the top gainers on 28 October, up 2.03-4.43% along with other names in that group.
-
Healthcare Services Sector Update Oct26 1 HSIE
The report states a BUY rating on Apollo Hospitals.
-
The report lists Apollo Hospitals among the top gainers, up 0.92-4.25%.
-
Daily Derivative and Technical snapshot 23 10 2026
The report notes Apollo Hospitals saw long buildup with OI change of 8.25% and price up 0.41%.
-
The report lists Apollo Hospitals Enterprise among the top losers, down 2.41-4.19%.
-
Healthcare Services Sector Update Oct26 HSIE
The report estimates a Sales/EBITDA impact of 0.5%/2.8% from the oncology drug price cap and maintains a BUY rating.
-
The report lists Apollo Hospitals Enterprise among the top losers, down 2.02-3.15%.
-
The report notes Apollo Hospital was among the top gainers, up 3.38-4.72%.
-
Daily Derivative Insight Oct 08 2026 08 10 2026 08
The note says call open interest is 91.2% of its record high and 2.0x the 20-day average.
-
Pharma and Healthcare Q2FY27 Preview HSIE
The report expects 19% YoY revenue growth from better occupancy and new bed additions, naming it a strong performer with margin improvement.
-
Daily Derivative and Technical snapshot 07 10 2026
The note lists Apollo Hospitals under short buildup with OI up 8.98% and price down 1.35% at 7,920.50.
-
The note lists Apollo Hospital among stocks showing weakness in the derivatives segment.
-
The report expects Apollo to post 19%/20%/26% YoY growth in sales/EBITDA/PAT in 2QFY27 and is set to operationalize ~620 beds across metro markets.
-
Pharma Sector Update Oct 26 HSIE
The note says it estimates a ~5% EBITDA impact for Apollo Hospital under the assumed margin-cap scenario and maintains a BUY rating.
Prices from Yahoo Finance, NSE close, delayed — indicative only, not for dealing. Solid markers sit on the exchange's own timestamp.
Targets, and what happened next
What each house published, and where the price has gone since. Orivam issues no calls of its own and takes no view on these.
| House | Published | Call | Entry | Target | Now | Progress | Standing |
|---|---|---|---|---|---|---|---|
| HDFC Securities | 06 Nov 2026, 06:42 | long | 8,446.00 | 9,990.00 | — | — | open by 2027-11-06 |
| HDFC Securities | 07 Oct 2026, 15:25 | long | 7,917.00 | 10,000.00 | 8,446.00 | 25% | open by 2027-10-07 |
Deadlines: 0 stated by the house, the rest set by Orivam’s convention — ten trading days for a technical call, twelve months for a price target. A target with no date cannot be judged, so one has to be chosen.
What the desks said
The report says Apollo's EBITDA grew 29% YoY across hospitals, HealthCo and AHLL segments, and raises concerns on trade margin impact on oncology while retaining BUY with revised TP INR9,990.
Read this note →The report lists Apollo Hospitals Enterprise among the top gainers on 28 October, up 2.03-4.43% along with other names in that group.
Read this note →The report states a BUY rating on Apollo Hospitals.
Read this note →The report lists Apollo Hospitals among the top gainers, up 0.92-4.25%.
Read this note →The report notes Apollo Hospitals saw long buildup with OI change of 8.25% and price up 0.41%.
Read this note →The report lists Apollo Hospitals Enterprise among the top losers, down 2.41-4.19%.
Read this note →The report estimates a Sales/EBITDA impact of 0.5%/2.8% from the oncology drug price cap and maintains a BUY rating.
Read this note →The report lists Apollo Hospitals Enterprise among the top losers, down 2.02-3.15%.
Read this note →The report notes Apollo Hospital was among the top gainers, up 3.38-4.72%.
Read this note →The note says call open interest is 91.2% of its record high and 2.0x the 20-day average.
Read this note →The report expects 19% YoY revenue growth from better occupancy and new bed additions, naming it a strong performer with margin improvement.
Read this note →The note lists Apollo Hospitals under short buildup with OI up 8.98% and price down 1.35% at 7,920.50.
Read this note →The note lists Apollo Hospital among stocks showing weakness in the derivatives segment.
Read this note →The report expects Apollo to post 19%/20%/26% YoY growth in sales/EBITDA/PAT in 2QFY27 and is set to operationalize ~620 beds across metro markets.
Read this note →The note says it estimates a ~5% EBITDA impact for Apollo Hospital under the assumed margin-cap scenario and maintains a BUY rating.
Read this note →Announcement timeline
No filings stored for this company yet.
Never miss the next one.
Orivam emails what the research desks published each trading morning, attributed and linked to the original notes. Free.
Get the daily brief